Cronos Group has finalized its acquisition of CanAdelaar B.V., the dominant licensed producer inside the Netherlands' adult-use cannabis pilot program known as the Wietexperiment. The deal, first announced in December 2025, closed Oct. 15, 2026, with Cronos paying a base purchase price of €57.5 million plus contingent earnout payments tied to CanAdelaar's performance in 2026 and 2027. For a company that has spent years talking about a "borderless" product strategy, this is the first time that strategy has a real address.
Why the Wietexperiment Matters to Operators Watching From Abroad
The Wietexperiment isn't a loosely tolerated gray market; it's a closed-loop supply chain built by regulators specifically to test what happens when cannabis production and retail sit entirely inside a licensed, trackable system. All 69 coffee shops across the program's 10 participating municipalities had to exit the legacy "tolerated" model and source exclusively from 10 licensed producers. No imports, no exports, no sales between producers - product moves one direction, from cultivator to retailer, inside a defined geography. That's a stricter chain-of-custody model than most U.S. state seed-to-sale systems attempt, and it gives regulators a cleaner dataset to evaluate before deciding whether to expand the pilot.
For operators and compliance teams elsewhere, the structure is worth studying. A fully closed supply chain removes a lot of the diversion risk that shows up in less controlled markets, but it also concentrates enormous leverage in whichever producers scale fastest. CanAdelaar, by supplying nearly all 69 coffee shops in the program, has effectively become the infrastructure the entire pilot runs on.
The Numbers Behind the Deal
CanAdelaar's financials tell a growth story that's already leveling off. Net revenue climbed from €15.2 million in 2024 to €40.6 million in the 12 months ended Sept. 30, 2025, then held roughly flat at €41.6 million annualized through the first half of 2026. Adjusted EBITDA actually declined over that same stretch, from €24.2 million to €20.1 million annualized, as the remaining licensed producers came fully online and competition intensified. That's a useful reminder: first-mover advantage in a pilot program has a shelf life. Once every competitor is licensed and operating, margin compression follows.
The purchase price - about 1.4x net revenue and 2.9x adjusted EBITDA on annualized 1H 2026 figures - reads as a disciplined multiple for a market-leading asset, not a speculative premium. Cronos is also structuring part of the consideration as contingent payments tied to future EBITDA, which shifts some performance risk back onto the deal rather than paying it all upfront.
What a Greenhouse Model Means for Wholesale Economics
- CanAdelaar is the only large-scale greenhouse cultivator among the 10 licensed producers; the rest operate indoor facilities, which typically carry higher energy and per-gram production costs.
- A 540,000-square-foot facility handling cultivation, processing, production and packaging under one roof reduces handoffs - and handoffs are where compliance logs, batch tracking and quality control tend to get messy.
- More than 60% of CanAdelaar's revenue still comes from dried flower, leaving meaningful room for derivative product categories permitted under the program, assuming Cronos can bring genetics and formulation work from its broader portfolio.
In practice, though, a cost advantage from greenhouse cultivation only matters if the regulatory window stays open long enough to amortize the investment. That's the real variable here.
The Expansion Question Nobody Can Answer Yet
The pilot currently covers 10 municipalities - Amsterdam isn't one of them - representing 69 of the Netherlands' 562 coffee shops and roughly 1.7 million of the country's 18.1 million residents. An interim government report published in September 2026 described initial experiences as predominantly positive, which is encouraging but far from a commitment to nationwide rollout. Cronos is clearly positioning for that possibility, framing the acquisition as a platform rather than a standalone asset. For other EU jurisdictions watching the Wietexperiment as a potential template, the real test isn't whether a closed supply chain can work operationally - this deal suggests it can - but whether lawmakers are willing to extend a controlled pilot into a permanent, larger-scale adult-use market. Age verification, lab testing and transparency requirements built into the pilot will likely stay central to that conversation, regardless of how far the geography expands.
